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Abstract
Escherichia coli O157 is a major cause of foodborne illness. Plasmids are genetic elements that 
mobilize antimicrobial resistance determinants including blaCMY β-lactamases that confer 
resistance to extended-spectrum cephalosporins (ESC). ESCs are important for treating a variety 
of infections. IncA/C plasmids are found among diverse sources, including cattle, the principal 
source of E. coli O157 infections in humans. IncI1 plasmids are common among E. coli and 
Salmonella from poultry and other avian sources. To broaden our understanding of reservoirs of 
blaCMY, we determined the types of plasmids carrying blaCMY among E. coli O157. From 1996 to 
2009, 3742 E. coli O157 isolates were tested. Eleven (0.29%) were ceftriaxone resistant and had a 
blaCMY-2-containing plasmid. All four isolates submitted before 2001 and a single 2001 isolate 
had blaCMY encoded on IncA/C plasmids, while all five isolates submitted after 2001 and a single 
2001 isolate had blaCMY carried on IncI1 plasmids. The IncI1 plasmids were ST2, ST20, and 
ST23. We conclude that cephalosporin resistance among E. coli O157:H7 is due to plasmid-
encoded blaCMY genes and that plasmid types appear to have shifted from IncA/C to IncI1. This 
shift suggests either a change in plasmid type among animal reservoirs or that the organism has 
expanded into avian reservoirs. More analysis of human, retail meat, and food animal isolates is 
necessary to broaden our understanding of the antimicrobial resistance determinants of ESC 
resistance among E. coli O157.
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1. Introduction
Escherichia coli is commonly found in the intestinal tracks of humans and animals and can 
be spread to food, soil, and water by fecal contamination. While most E. coli is commensal, 
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Shiga-toxin producing E. coli (STEC) has emerged as a significant public health threat. One 
particular STEC, O157, is a major cause of foodborne illness and can result in diarrhea, 
hemorrhagic colitis and hemolytic-uremic syndrome in humans [1]. E. coli O157 has been 
the cause of many foodborne disease outbreaks and much research has focused on the 
prevalence of this organism in beef cattle and the resulting contamination of ground beef [2]. 
However, E. coli O157 has been identified among additional food animals including dairy 
cattle, swine, and poultry [3–5].
Antimicrobial treatment of STEC infections is currently not recommended due to bacterial 
lysis and subsequent Shiga toxin release. However, some studies have suggested that early 
administration of some antimicrobials may prevent disease progression [6–8]. More 
recently, a retrospective study of treatment outcomes from the 2011German E. coli O104:H4 
outbreak concluded that antimicrobials may be an effective treatment [9]. Besides their use 
in human therapeutics and veterinary medicine, antimicrobials are also used in food animal 
production for growth promotion and disease prevention. This has likely led to the selection 
of antimicrobial resistance among STECs in food animals [10]. By identifying and 
characterizing the mechanisms of resistance and how they are spread, we hope to better 
understand the relationships between resistance attributes and possible sources of human 
infection among food animals and their retail meat.
Extended-spectrum cephalosporins (ESCs) are an important class of drugs used in human 
and veterinary medicine, and veterinary uses include treatment of food animals. Resistance 
to ESCs is usually mediated by the production of certain classes of β-lactamases, including 
AmpC β-lactamases, commonly encoded by blaCMY-2 genes [11]. Plasmids are genetic 
elements that can mobilize antimicrobial resistance determinants, including blaCMY β-
lactamases. Plasmids can be distinguished by their incompatibility features (reflecting 
replication) and can therefore be grouped into several replicon (Inc) types [12]. To broaden 
our understanding of reservoirs of cephalosporin resistance among E. coli O157, we 
identified and characterized cephalosporin resistant isolates from humans. We identified the 
mechanism of resistance, determined if resistance was plasmid mediated and if so, 
determined the types and mobility of these plasmids. We also examined the genetic 
relatedness of isolates to determine if clonal spread could be responsible for the 
cephalosporin resistance
2. Materials and Methods
2.1 Isolate collection and testing
E. coli O157 isolates were obtained from specimens from ill persons submitted to clinical 
laboratories in the United States and subsequently forwarded to state public health 
laboratories. Participating state public health laboratories serotyped and submitted every 
twentieth E. coli O157 to the CDC National Antimicrobial Resistance Monitoring System 
(NARMS) laboratory for susceptibility testing. The Enteric Diseases Laboratory Branch at 
CDC also receives representative isolates from foodborne disease outbreaks from state and 
local public health laboratories, and NARMS performs susceptibility testing on those 
isolates as well. Broth microdilution (Sensititre®, Trek Diagnostics, Westlake, OH) was 
used to determine the minimum inhibitory concentrations (MIC) for 15 antimicrobial agents: 
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amikacin, ampicillin, amoxicillin-clavulanic acid, cefoxitin, ceftiofur, ceftriaxone, 
chloramphenicol, ciprofloxacin, gentamicin, kanamycin, nalidixic acid, streptomycin, 
sulfamethoxazole/sulfisoxazole, tetracycline, and trimethoprim-sulfamethoxazole. 
Resistance was defined by the Clinical and Laboratory Standards Institute (CLSI) 
interpretive standards, when available [13]. For streptomycin, where no CLSI interpretive 
criteria for Enterobacteriaceae isolated from humans exist, the resistance breakpoint is 64 
mg/L [14]. Testing was performed according to the manufacturer’s instructions and using 
the following quality control strains: E. coli ATCC 25922, Staphylococcus aureus ATCC 
29213, Enterococcus faecalis ATCC 29212, and Pseudomonas aeruginosa ATCC 27853.
2.2 PCR amplification and sequencing of blaCMY and the promoter of ampC
For each isolate, DNA was isolated by lysing the bacteria at 95°C and collecting the 
supernatant following centrifugation for 10 min at 20,000 g (Sorvall RC5B Plus, SS-34 
rotor, Thermo Fischer Scientific Inc., Waltham, MA). PCR reactions contained 1x Hot Start 
PCR Master Mix (Qiagen Inc., Valencia, CA), 0.4µM of each primer, 5µl template DNA and 
sterile PCR water to a final volume of 50µl. Thermal cycling was performed using the 
following conditions: 15 min at 95°C, followed by 30 cycles of 95°C for 30 s, 56°C for 30 s 
and 72°C for 90 s. To determine the presence of blaCMY genes, primers ampC1 and ampC2 
were used [15]. These primers and internal primers CMYSEQ1 (5’-
GGTTGCAGGACGCGTCTG-3’) and CMYSEQ2 (5’-CCGCAATGGACTCCGGGC-3’) 
were used to sequence the entire blaCMY gene. PCR amplification of the promoter of ampC 
was performed with primers AB1 and AmpC2 as previously described [16]. Sequencing was 
performed using Big Dye version 3.1 (Applied Biosystems, Foster City, CA) and sequence 
reactions are cleaned with Centri-sep plates (Princeton Separations, Adelphia, NJ). The 
reactions are electrophoresed through POP-7 polymer (Applied Biosystems) on a 3730 DNA 
Analyzer (Applied Biosystems) equipped with a 48-capillary, 50 cm array. Sequence 
analysis was performed using Lasergene 8 software (DNASTAR Inc, Madison, WI). The 
detection of genetic elements associated with the blaCMY gene was performed as previously 
described [17, 18].
2.3 Plasmid purification and characterization
Purified plasmid DNA was used to transform laboratory E. coli strains, separate the blaCMY 
plasmids from other plasmid types prior to replicon typing, and perform plasmid multi-locus 
sequence typing (pMLST). Plasmids were purified using the QiaFilter Midi kit (Qiagen 
Inc.), following a modified manufacturers protocol as previously described [19]. 
Electroporation of each plasmid into E. coli DH10B Electromax competent cells (Invitrogen, 
Carlsbad, CA) was performed as previously described [19]. Cells were plated on LB agar 
plates containing 100 mg/L of ampicillin (Sigma-Aldrich, St. Louis, MO). Plasmids were re-
purified from a single blaCMY PCR-positive transformant to isolate a single plasmid from 
each isolate. Purification was performed as described above with the additional modification 
of growing the cells overnight in 25 ml of LB broth with 100 mg/L of ampicillin. Plasmid 
PCR-based replicon typing (PBRT) was performed as previously described [12]. Plasmid 
multi-locus sequence typing was performed on IncI1 plasmids as previously described [20]. 
Sequences were submitted to the plasmid multi locus sequence type (pMLST) web page 
(http://pubmlst.org/plasmid/) and the ST type was determined. Conjugation experiments 
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were performed as previously described using a sodium azide resistant J53 E. coli strain as 
recipient (gift from G. Jacoby) [21]. Transconjugants were selected on LB containing 200 
mg/L sodium azide and 100 mg/L of ampicillin. A single colony from each transformation 
experiment was PCR-screened for the blaCMY gene to confirm successful conjugation. 
Conjugation efficiency was equal to the number of recipient cells divided by the number of 
donor cells. Conjugation experiments were performed in duplicate. A single representative 
experiment is shown in Table 2. Plasmid size was determined using a pPFGE protocol [19]. 
Plasmids from E. coli strains PDK9 and V517, which contain several plasmids that range in 
size from 2.2 to 220 kb, were also extracted and used as size standards on the gels [22].
2.4 Pulsed-Field Gel Electrophoresis (PFGE)
PFGE was performed according to the CDC PulseNet protocol and all PFGE profiles 
generated were submitted to the PulseNet national database [23]. Gel images were captured 
using the GelDoc XR system (Bio-Rad Laboratories) and Quantity One 1-D analysis 
software (Bio-Rad Laboratories). Pattern analysis and UPGMA dendrogram generation were 
performed using BioNumerics software (Applied Maths, Saint-Martens-Latem, Belgium) 
with the Dice coefficient and tolerance of 1.5%.
3. Results
3.1 Identification of ceftriaxone resistant isolates
From 1996 to 2009, CDC NARMS received 3742 E. coli O157 isolates and tested them for 
antimicrobial susceptibility to 15 antimicrobials. Eleven (0.29%) isolates were resistant to 
the third generation cephalosporin ceftriaxone (Table 1). All were isolated between 2000 
and 2009 and were confirmed as serotype O157:H7. Ten of the eleven resistant isolates were 
submitted as part of routine surveillance; the single 2009 isolate was from an outbreak with 
unknown source (Table 1). The resistant isolates originated from 10 different states, with 
two submitted from California. All isolates were from stool samples. The patients included 
six females, three males, and two persons whose gender was not reported. Their ages varied 
from 1 to 83 years, with a median of 15 years. All cephalosporin-resistant isolates were also 
resistant to ampicillin, amoxicillin/clavulanic acid, cefoxitin, and ceftiofur. The four isolates 
obtained in 2000 and the one obtained in 2001 were also resistant to chloramphenicol, 
sulphamethoxazole/sulfisoxazole, streptomycin, and tetracycline. One of the two 2001 
isolates and all five isolates submitted after 2001 displayed no additional resistance.
3.1 Determination of the genetic relatedness of the isolates
To determine the genetic relatedness of isolates, pulsed-field gel electrophoresis (PFGE) 
was performed both with XbaI- and BlnI-restricted DNA and a dendrogram was constructed 
(Figure 1). All isolates showed a degree of relatedness (>75%) and two sets of two isolates 
were indistinguishable by both enzymes. Interestingly, these 4 isolates were among the 
earliest identified by NARMS (year 2000–01). All of the remaining isolates had different 
PFGE patterns.
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3.2 Characterization of the ceftriaxone resistance determinant
The observed resistance to cefoxitin, a cephamycin, and amoxicillin/clavulanic acid, a β-
lactam/β-lactam inhibitor combination, suggests the presence of an AmpC-like β-lactamase. 
All isolates were positive for a blaCMY gene by PCR (the four isolates from year 2000 were 
previously shown to be blaCMY positive) [24]. Sequence analysis identified genes as 
blaCMY-2 (Table 2). No mutations were identified within the promoter region of the 
chromosomal copy of ampC (data not shown). To determine if the blaCMY-2 genes were 
plasmid-encoded, plasmid DNA was purified from the isolates and transferred to laboratory 
E.coli strains by electroporation. The blaCMY-2 genes and corresponding resistance 
phenotype transferred from all 11 isolates, confirming that the blaCMY-2 genes for all 11 
isolates were located on plasmids. To further characterize the blaCMY-2 plasmids, PCR-
based incompatibility testing (PBRT) was performed on the transformants. The five isolates 
submitted through 2000 and a single 2001 isolate had blaCMY-2 encoded on IncA/C 
plasmids, while all five isolates submitted after 2001 and the remaining 2001 isolate had 
blaCMY-2 carried on IncI1 plasmids (Table 2). Interestingly, the 4 isolates which had paired 
PFGE patterns (2 matched sets) all had IncA/C-blaCMY-2 plasmids. These IncA/C-blaCMY-2 
plasmids varied in size from 100–150 kb, while the IncI1-blaCMY-2 plasmids varied from 
90–110 kb. To determine if these plasmids were competent for conjugation, a conjugation 
efficiency assay was performed. Both types of plasmids were able to transfer to the recipient 
strain by broth conjugation. The IncA/C plasmids displayed a wide range of conjugation 
efficiency; three had high/moderate efficiency (10−2, 10−3) while two of the IncA/C 
plasmids had very low efficiency (10−8, 10−9). In contrast, all of the IncI1 plasmids 
displayed high conjugation efficiency (10−1, 10−2). The genetic elements associated with the 
blaCMY genes were investigated by PCR analysis. All eleven blaCMY genes were located 
downstream of an ISEcp1 element, but 4 of these elements (found in plasmids pAM17504, 
pAM18099, pAM25705, and p2009EL1288) contained ISEcp1 elements with 5’ deletions 
(data not shown). No ISCR1 or IS26 elements were identified.
Antimicrobial susceptibility testing performed on the plasmid transformants identified 
additional resistance phenotypes conferred by all of the IncA/C-blaCMY-2 plasmids, 
including resistance to chloramphenicol, sulphamethoxazole/sulfisoxazole, streptomycin, 
and tetracycline. None of the IncI1-blaCMY-2 plasmids conferred additional resistance. To 
further characterize the IncI1-blaCMY-2 plasmids, plasmid multi-locus sequence typing 
(pMLST) was performed on the plasmid containing transformants. Of the six IncI1-
blaCMY-2 plasmids, three were sequence type (ST) 23, two were ST2, and one was ST20 
(Table 3). There is currently no pMLST scheme for IncA/C plasmids.
4. Discussion
Extended-spectrum cephalosporins (ESC) are an important class of antimicrobials drugs 
used in human medicine and veterinary medicine, including in food animal production 
settings [25]. Although ESCs are rarely used for the treatment of STEC infections in 
humans, understanding the mechanisms of ESC resistance and transmission of ESC-resistant 
bacteria may provide us with clues into possible sources of human infection. The percentage 
of ESC resistance among E. coli O157 isolates collected from ill humans by CDC-NARMS 
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remained low (0.29%) over the last 13 years. The eleven ESC resistant isolates identified in 
this study were spread out over time (2000–2009) and location (submitted by 10 states). 
PFGE analysis showed a variety of subtypes and only 2 sets of 2 isolates were 
indistinguishable. This suggests that the observed ESC resistance among E. coli O157:H7 
isolates in the U.S. is not being spread clonally.
All eleven isolates displaying ESC resistance were positive for the blaCMY-2 gene, a 
common ESC-resistance determinant found among Salmonella in the United States [19]. E. 
coli also have a chromosomal ampC gene which can be upregulated due to promoter 
mutations, resulting in cephalosporin resistance. However, no mutations were identified 
within the promoter region of ampC among our isolates. Beside resistance to the ESCs 
ceftriaxone and ceftiofur, the blaCMY-2 genes also conferred resistance to ampicillin, 
amoxicillin/clavulanic acid, and cefoxitin. All of the blaCMY-2 genes were located 
downstream of ISEcp1 elements which were located on plasmids, common for blaCMY-2 
genes. Depending on their origin or replication, some plasmids can be typed or grouped 
based on their compatibility within a host bacteria. Two plasmid types, IncA/C and IncI1, 
were found to carry the blaCMY-2 gene among our isolates. Additional characteristics of the 
IncA/C- blaCMY-2 and IncI1- blaCMY-2 plasmids were similar to what was previously 
observed for these plasmids isolated from Salmonella [11, 19, 26–28]. Specifically, IncA/C 
plasmids are usually large (>150kb), have varying conjugation efficiencies, and carry 
additional resistance determinants, while IncI1- blaCMY-2 plasmids are smaller (~100kb), 
highly mobile (conjugation efficiency 10−1–10−2), and usually do not carry additional 
resistance determinants. IncA/C and IncI1 are common plasmid types found to carry 
blaCMY-2 among enteric bacteria in the U.S. However, we were surprised to see a shift in 
2001, from IncA/C- blaCMY-2 plasmids to IncI1- blaCMY-2 plasmids among our ESC 
resistant E. coli O157:H7. IncA/C plasmids have been found among diverse sources, 
including cattle, which are believed to be the principal reservoir for E. coli O157:H7 and the 
major source of food products transmitting the organism to humans [2]. In contrast, IncI1 
plasmids are most commonly found among E. coli and Salmonella isolated from poultry and 
other avian sources and encode a type IV pilus system which may be involved in avian 
pathogenicity [11, 19, 26, 29].
Although based on a very small number of isolates, this shift in plasmid type carrying the 
blaCMY-2 gene from IncA/C to IncI1 suggests either a possible change in blaCMY-2- plasmid 
type among cattle (from IncA/C to IncI1) or a possible expansion of the E. coli O157 
reservoir among food animal sources (from cattle to poultry). The six IncI1- blaCMY-2 
plasmids could be further typed into sequence types (ST) and compared with additional 
isolates with similar plasmids in the plasmid multi-locus sequencing database [30]. ST23 
plasmids have been identified previously from blaCMY-2 positive isolates, including an E. 
coli clinical isolate obtained in Canada and Salmonella ser. Heidelberg clinical and a retail 
meat (chicken breast) isolates obtained here in the U.S. [11, 19, 31]. ST20 and ST2 plasmids 
have been found among blaCMY-2 positive E. coli and Salmonella from multiple sources, 
including environmental and clinical samples collected in Canada and the U.S [19, 31]. 
These additional isolates, similar to our six isolates with IncI1 plasmids, were also collected 
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after 2001. This further suggests that these IncI1 plasmids may be present in different types 
of enteric bacteria and in different sources.
We conclude that the observed cephalosporin resistance among E. coli O157:H7 is due to 
plasmid-encoded blaCMY genes and that plasmid types appear to have shifted from IncA/C 
to IncI1. This shift suggests a possible a change in plasmid type among animal reservoirs or 
the possibility that the organism has expanded into avian reservoirs. While a considerable 
amount of research has been performed on ESC resistance in generic E. coli, very little is 
known about resistance among STEC or serogroup O157 specifically. In particular, analysis 
and characterization of E. coli O157:H7 isolates from food animals and retail meat is 
necessary to better understand transit of and selection pressures for plasmid-mediated ESC 
resistance. Better understanding of the connection between plasmid type and animal 
reservoir may contribute to determination of source of human infection.
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PFGE patterns of ESC resistant E. coli O157:H7 isolated from humans in the United States. 
Dendrogram of percent genetic identity by PFGE was generated using BioNumerics based 
on XbaI and BlnI restriction digestion. Pattern analysis and UPGMA dendrogram generation 
were performed using BioNumerics software (Applied Maths, Saint-Martens-Latem, 
Belgium) with the Dice coefficient and tolerance of 1.5%. Percent identity is located above 
the dendrogram. Isolate year, isolate number, and plasmid incompatibility type are listed to 
the right of the dendrogram.
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